Baxter Resources for Products Authorized for Temporary Importation
Baxter’s North Cove manufacturing site was significantly impacted by the rain and storm surge from Hurricane Helene. Supporting our employees in the impacted communities, bringing the North Cove facility back online and helping to ensure ongoing supply to patients are our top priorities.
While healthcare practitioners should continue to use their professional judgement in assessing the needs and resources of their individual organizations and patients, this site is intended to help support product management and conservation strategies and efforts. Our Medical Affairs team is also available at [email protected].
Products Authorized for Temporary Importation
In order to help with the supply issue resulting from Hurricane Helene, the FDA authorized temporary importation into the United States (U.S.) of certain foreign-approved Baxter products that are manufactured in other countries. Temporary authorization allows for temporary, controlled importation of foreign-approved drugs to help mitigate U.S. drug shortages and differs from emergency use authorization (EUA), which provides an expedited approval pathway for products used in an emergency situation to protect against chemical, biological, radiological and nuclear threats, including infectious diseases. Additionally, Baxter manufactures and distributes FDA-approved products—some of which may be manufactured in foreign countries. As part of our FDA approval for the products, we import and distribute those products in the U.S. market.
This document contains Baxter Product Code and Lot information and the associated Dear Healthcare Provider letters for products that have received temporary importation authorization from FDA as they become available in the U.S. market. This document will be updated as new Product Codes/Lots become available.
Dear Healthcare Professional Letters
Dear Healthcare Professional (DCHP) letters for each Baxter product authorized for temporary importation in the U.S. are listed below by solution type and product code as they become available in the U.S. market. These will be added as new Product Codes/Lots become available.
For additional information beyond what is available in the letter, please refer to Baxter U.S. Medical Information Online: https://medinfo.baxter.com. Self-service portal intended for Healthcare Professionals to search and download frequently requested product information.
Side-by-Side Comparisons for Clinical Use
For Baxter products authorized for temporary importation in the U.S., available side-by-side comparisons are listed below by solution type and product code as they become available in the U.S. market. These will be added as new Product Codes/Lots become available.
Order Entry & Compounders
For information on how to add concentrated glucose to the Baxter order entry software (Abacus) and automated compounding device (ExactaMix), please see the Adding Glucose 50% to ExactaMix and Abacus educational material.
Videos & Webinars
WEBINAR - Dextrose, USP vs Glucose – What Are The Differences?
Presented by:
Jeff Brittain, PharmD, BCPS, BCMAS, Senior Manager, Baxter Medical Affairs
Watch this educational webinar, provided by Baxter Medical Affairs, for information on differences between dextrose, USP and glucose.
Baxter U.S. Medical Information Online: https://medinfo.baxter.com
Self-service portal intended for Healthcare Professionals to search and download frequently requested product information.